Low-dose aspirin no help for CVD in healthy seniors

No major protective effect but there is increased risk of bleeding

Daily low-dose aspirin for primary prevention of cardiovascular disease in the healthy elderly is likely to do more harm than good, an Australian landmark study suggests.

There was no difference in the primary end-point of disability-free survival between the two trial arms, in which 19,500 elderly people were randomly allocated to either aspirin (100mg/day) or placebo, the results of the ASPREE (Aspirin in Reducing Events in the Elderly) trial show.

The trial was stopped six months early, in June 2017, when it became clear that there would be no difference in results for the primary end